Compute scales; cure capital follows
The cure race is not slowing: 21,077 active cure-related trials are in motion while 28 new wire signals and 6 new cure research items landed in the last 24 hours. The clearest pattern is not a single breakthrough but a convergence of capital, infrastructure, and AI: MindRank raised $52 million for an AI-native drug engine, while generative AI is being paired with physics to design new antibiotics and tumor-response platforms are getting faster and more predictive. At the same time, the broader compute stack is hardening — from China’s 100,000-card AI supercluster to near-instant isolated serverless runtimes — which matters because modern biology increasingly depends on who can scale intelligence first. The window is still open.
In the last 24 hours, 28 new wire signals and 6 new cure research developments were added, including a $52 million Series B for MindRank and multiple AI-enabled drug discovery and validation advances.
Capital and compute are now directly shaping how fast new therapies can be designed, screened, and de-risked, so the winners will be the teams that can turn intelligence into validated biology before the next wave closes in.
Watch whether AI-native drug discovery, ex vivo validation, and infrastructure-scale compute keep compounding together, because that alignment is what can shorten the path from hypothesis to human trial.